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Abstract: The aim of this study was to determine the efficacy of inactive Rhodococcus equi vaccine candidates included that
bacterin+aluminum hydroxide (Al(OH)3), bacterin+VapA+(Al(OH)3), bacterin+Montanide IMS 3012 (IMS), bacterin+VapA+IMS,
and live vaccine using mice as a model. The efficacy of vaccine was evaluated according to clinical findings, humoral and cellular
immunity (levels of INF-g and IL-4), and results of microbiological culture from internal organs in dead or sacrificed mice. Inactive R.
equi vaccines were subcutaneously administered to mice three times at 15-day intervals and live vaccine was intraperitoneally injected
once. Fifteen days after the last vaccination, aerosol challenges were carried out with the pathogenic R. equi VapA+K2002 strain in all
groups. Two mice were sacrificed from each challenge groups on days 1, 3, 5, and 7. The antibody titers of vaccinated mice were found to
be significantly higher than those of the controls. The largest number of INF-g positive samples were detected in the bacterin+VapA+IMS
and bacterin+IMS groups. IL-4 positivity was determined only in live vaccine groups. The lowest reisolation rate of R. equi from internal
organs was observed in the bacterin+VapA+IMS group. It was concluded that R. equi vaccines, and especially bacterin+VapA+IMS, are
useful to protect mice against R. equi infection.
Key words: Rhodococcus equi, vaccine, mice model, VapA, Montanide IMS 3012, Al(OH)3

1. Introduction
Rhodococcus equi is a gram-positive, nonmotile, obligate
aerobic, intracellular microorganism. This organism
is a facultative pathogen that causes pneumonia in
foals. This pathogen also causes ulcerative enterocolitis,
osteomyelitis, and septic arthritis in rare cases. R. equi is
present in the soil and in horse feces. Foals are thought
to become infected when they ingest or breathe in soil,
dust, or fecal particles harboring the bacteria within
the first few days of life (1,2). Inhalation of aerosolized
virulent R. equi from the environment and intracellular
replication within alveolar macrophages are essential
components of the pathogenesis of R. equi pneumonia
in foals (3). Virulence of R. equi is associated with the
presence of plasmids of 80–90 kb that encode the 15–17
kDa lipoprotein virulence-associated protein A (VapA)
(4). Clinical symptoms typically appear in less than 6
months. However, protection of the newborn foal is most
important during the first week (5). In addition, R. equi
may cause infections in the lungs of horses (6).
* Correspondence: zafersayin@gmail.com

R. equi pneumonia significantly impacts the equine
industry by causing financial losses because foals that
recover from the disease are less likely to race as adults
(7). The strategies used to protect against R. equi
infection remain unsuccessful in foals. Although the
use of a combination of antibiotics, such as rifamycin
and erythromycin, is preferred in the treatment of this
infection, the therapeutic effects are inconsistent due to
bacteria that grow within cells and create granulomatous
abscesses. In addition, the long-term use of antibiotics has
potential risks, such as the development of resistance to
antibiotics. The immunization of mares has been suggested
by several researchers to prevent R. equi infection in foals
(8–10).
In this study, the efficacy of R. equi vaccines was
determined in mice for the protection of Arabian foals
against R. equi infection. To achieve this aim, 4 inactive
vaccine candidates and a live vaccine were prepared using
the VapA+K2002 strain of R. equi.
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2. Materials and methods
This research was approved (15/02/2008 and 2008/010)
by the Ethics Committee of the Faculty of Veterinary
Medicine of Selçuk University in Konya, Turkey.
2.1. Inactive vaccines
R. equi of the VapA+K2002 strain, which was isolated from
a dead foal at the Karacabey Arabian Horse Breeding
Farms in Turkey, was cultured in brain-heart infusion
(BHI) (Oxoid, Basingstoke, UK) supplemented with 1%
yeast extract (Oxoid) at 37 °C for 48–60 h. The bacterial
pellet was harvested by centrifugation at 6000 × g and
washed three times with TBS (Tris, 19 nM, pH 7.4; NaCl,
150 mM). The bacterial concentrations were adjusted to 5
× 109 CFU/dose in 3 mL and inactivated using formalin
(0.5% v/v).
The supernatant of the bacterial culture was filtered
and concentrated for the VapA antigen using a 10 kDa
Sartacon Slice 200 cassette filter (Sartorius AG, Göttingen,
Germany). The VapA protein content was measured using
a commercially protein assay kit (Protein Assay, Lowry,
Bio-Rad, Richmond, CA, USA).
The inactive bacterin and bacterin+VapA vaccines
included 5 × 109 CFU of R. equi/dose and 5 × 109 CFU of R.
equi plus 0.5 mg of VapA/dose, respectively. The inactive
vaccines were absorbed using 4% Al(OH)3 gel (Vetal A/S,
Adıyaman, Turkey) (11–13) or homogenized with an
equal volume of mineral oil adjuvant (Montanide IMS
3012, Seppic, Castres, France) (14).
2.2. Live vaccine
Attenuated R. equi of the VapA+K2002 strain was cultured
into BHI supplemented with 1% yeast extract at 37 °C for
48 h. After washing three times, the bacterial concentration
was adjusted to 1.2 × 109 CFU/dose. Antigen and stabilizer
(10% skim milk powder) were mixed equally and the
vaccines were lyophilized into small vials as a single
dosage.

2.3. Vaccination and challenge
All vaccine doses were designed to be 3 mL for mare
vaccination (15), and mice were vaccinated with 0.2 mL of
vaccine. The challenge and seropotency groups included
108 and 48 mice, respectively (Table 1). Inactive vaccines
(0.2 mL) were administered subcutaneously three times at
15-day intervals to the challenge and seropotency groups.
The live vaccine (0.2 mL) was injected intramuscularly one
time. After vaccination, adverse reactions were recorded
after the observation of animal behavior and palpation
of the injection site. Twenty-six mice were maintained as
controls for the challenge (18 mice) and seropotency (8
mice) groups.
A total of 15 days after the third vaccination, the mice
in the challenge groups were challenged with an aerosol
administration of 1 × 109 CFU of the R. equi VapA+S2002
strain using a nebulizer (Omron, Kyoto, Japan) in a special
cabin. The mice were observed for morbidity and mortality
for 14 days (16). After the challenge, two mice in each
group were sacrificed on each sampling day (i.e. the 1st,
3rd, 5th, 7th, and 14th days). The amount of clearance of R.
equi bacteria from the lungs was determined. In addition,
the internal organs (i.e. the liver, spleen, kidney, heart, and
lungs) of the mice were cultured on sheep blood (10% v/v)
agar (Oxoid) and incubated under aerobic conditions at 37
°C for 24 h to reisolate R. equi.
2.4. Measurement of INF-g and IL-4
Blood samples were obtained retroorbitally from mice
from the challenge and seropotency groups on days 5 and
15. The levels of INF-g and IL-4 (pg/mL) were measured
using the commercially available Mouse IL-4 ELISA
Ready-Set-Go kit (code number: 88-7044), eBioscience,
San Diego, CA, USA) and Mouse IFN-g ‘Femto-HS’
High Sensitivity ELISA Ready-Set-Go kit (code number:
88-8314), (eBioscience), respectively, according to the
manufacturer’s instructions.

Table 1. Numbers of mice in the challenge and seropotency groups.
Challenge group

Seropotency group

Vaccine types

For antibody, IL-4, and INF-g
measurement

Sacrificed for bacterial
reisolation

For antibody, IL-4, and INF-g
measurement

Bacterin+Al(OH)3

8

10

8

Bacterin+VapA+Al(OH)3

8

10

8

Bacterin+IMS

8

10

8

Bacterin+VapA+IMS

8

10

8

Live vaccine

8

10

8

Control

8

10

8

Total

48

60

48
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2.5. Serological monitoring in the groups
To determine the antibody titers in the mice, a homemade
ELISA tool was used. ELISA was performed according to
the procedure described by Takai et al. (17). Blood samples
were obtained from the challenge and seropotency
groups to determine the presence of anti-R. equi specific
antibodies using ELISA on vaccine days 0, 15, and 30. In
addition, blood samples were obtained from challenged
mice on days 5 and 14 after challenge and on days 15 and
25 after the last vaccination in the seropotency groups.
2.6. Statistical analysis
The significance of differences observed within the groups
was assessed using analysis of variance (ANOVA).

antibody titers were observed in mice vaccinated with
the bacterin+VapA+IMS and bacterin+IMS vaccine
candidates. After the third vaccination, antibody titers
were not increased in the live vaccine group, but antibody
titers gradually increased in the other vaccine groups
(Figure 1).
3.2. Challenge
A decrease in antibody titers was observed in mice
vaccinated with bacterin+IMS, bacterin+Al(OH)3, and
bacterin+VapA+Al(OH)3 on the 5th day after challenge.
However, an increase was observed in mice vaccinated
with bacterin+VapA+IMS. While antibody titers were
decreased in mice vaccinated with bacterin+VapA+IMS
on the 15th day after challenge, titers increased in the
other vaccine groups. In addition, an increase in antibody
titers was observed in control mice on the 5th and 15th
days after challenge (Figure 2).
The INF-g positivity rates of vaccinated mice in
the challenge and seropotency groups were 0.344,
0.531, 0.687, 0.750, and 0.281 in the bacterin+Al(OH)3,

3. Results
3.1. Seropotency
After the 1st, 2nd, and 3rd vaccinations, higher antibody
titers were observed in blood samples from the vaccinated
groups than in samples from the controls. A comparison
of the vaccinated groups revealed that the highest
Seropotency groups

3.5

Control
Bacterin+AlOH3

Optical density (OD)

3

Bacterin+IMS

2.5

Live

2

Bacterin+VapA
+AlOH3
Bacterin+VapA
+IMS

1.5
1
0.5
0
1st

2nd

3rd

4th

5th

Sampling (1st, 2nd, and 3rd sampling; the time of vaccination, 4th and 5th
sampling; 15 days and 25 days after the last vaccination)

Figure 1. Antibody titers of seropotency groups.
Challenge groups

3.5

Control
Bacterin+AlOH3

Optical density (OD)

3

Bacterin+IMS

2.5

Live

2

Bakterin+VapA
+AlOH3
Bacterin+VapA
+IMS

1.5
1
0.5
0

1st

2nd

3rd

4th

5th

6th

Sampling (1st, 2nd, and 3rd sampling; the time of vaccination, 4th and 5th
sampling; 5 days and 14 days after the last vaccination)

Figure 2. Antibody titers of challenge groups.
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bacterin+VapA+Al(OH)3, bacterin+IMS, bacterin+VapA+
IMS, and live vaccine groups, respectively. These rates
were higher in vaccinated mice than in controls, and the
highest result was detected in the bacterin+VapA+IMS
group (Table 2).
IL-4 positivity (0.468) was only determined in the live
vaccine group; it was not determined in the controls or in
the other vaccine groups (Table 3).
The R. equi numbers in the lungs of vaccinated
mice were lower than those observed in the controls.
The R. equi numbers were 77.7 × 104, 8.6 × 104, 8.4 ×
104, 5.1 × 104, 2 × 104, and 9.6 × 104 CFU/mL in the
control, bacterin+Al(OH)3, bacterin+VapA+Al(OH)3,
bacterin+IMS, bacterin+VapA+IMS, and live vaccine
groups, respectively (Table 4).
The numbers of mice with R. equi-positive internal
organs (except lungs) in the vaccinated groups were
significantly lower than in the controls. The rates (R values)
of R. equi-positive lungs were 1.0 in the controls and 9.03,
9.25, 15.23, 38.85, and 8.09 in the bacterin+Al(OH)3,

bacterin+VapA+Al(OH)3, bacterin+IMS, bacterin+VapA+
IMS, and live vaccine groups, respectively (Table 4).
The rates of other R. equi-positive internal organs were
0.775 in the controls and 0.200, 0.250, 0.075, and 0.300
in the bacterin+Al(OH)3, bacterin+VapA+Al(OH)3,
bacterin+IMS, bacterin+VapA+IMS, and live vaccine
groups, respectively (Table 5).
4. Discussion
R. equi infection is widespread around the world and leads
to death in 3% of foals (9). To date, no licensed vaccine is
available for the prevention of R. equi. In this study, the
efficacy of inactive and live R. equi vaccine candidates were
determined for the protection of Arabian foals using mice
as a model. To achieve this aim, 4 inactive vaccines and a
live vaccine were prepared using the VapA+K2002 strain
of R. equi, which was isolated from a foal infected with R.
equi.
VapA is important in immunity against R. equi
and stimulates Th1 immunity. Although the use of an

Table 2. IFN-g results obtained in mice.

Groups

Challenge

Seropotency

General

5th day

15th day

5th day

15th day

Positive/total

Rate

Control

1*/8**

2/8

1/8

0/8

4/32

0.125

Bacterin+Al(OH)3

3/8

4/8

2/8

2/8

11/32

0.344

Bacterin+VapA+Al(OH)3

2/8

4/8

4/8

6/8

17/32

0.531

Bacterin+IMS

6/8

8/8

4/8

4/8

22/32

0.687

Bacterin+VapA+IMS

7/8

8/8

4/8

5/8

24/32

0.750

Live vaccine

2/8

3/8

4/8

2/8

9/32

0.281

*IFN-g-positive mice number/**Total mice number.
Table 3. IL-4 results obtained in mice.

Groups

Challenge

Seropotency

General

5th day

15th day

5th day

15th day

Positive/total

Rate

Control

0*/8**

0/8

0/8

0/8

0/32

0

Bacterin+Al(OH)3

0/8

0/8

0/8

0/8

0/32

0

Bacterin+VapA+Al(OH)3

0/8

0/8

0/8

0/8

0/32

0

Bacterin+IMS

0/8

0/8

0/8

0/8

0/32

0

Bacterin+VapA+IMS

0/8

0/8

0/8

0/8

0/32

0

Live vaccine

4/8

4/8

5/8

2/8

15/32

0.468

*IL-4-positive mice number/**Total mice number.
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Table 4. R. equi numbers in the lungs of vaccinated and control mice after challenge (×104).
Days

Total

Rate

Groups

1

3

5

7

14

Control

7.0

11.9

31

17.9

9.9

77.7

1.00

Bacterin+Al(OH)3

2.5

6.0

0

0.1

0

8.6

9.03

Bacterin+VapA+Al(OH)3

1.5

6.5

0.3

0.1

0

8.4

9.25

Bacterin+IMS

0.6

2.8

0.8

0.7

0.2

5.1

15.23

Bacterin+VapA+IMS

0.4

1.4

0

0.1

0.1

2.0

38.85

Live

3.1

2.0

1.1

3.4

0

9.6

8.09

Total

Rate

*CG/ VG

*CG: control group/VG: vaccine group
Table 5. Reisolation rate of R. equi from internal organs (i.e. heart, liver, spleen, and kidneys).

Groups

Days after challenge
1

3

5

7

14

Control

2*/8**

7/8

6/8

8/8

8/8

31/40

0.775

Bacterin+Al(OH)3

1/8

0/8

2/8

4/8

1/8

8/40

0.200

Bacterin+VapA+Al(OH)3

0/8

0/8

2/8

6/8

2/8

10/40

0.250

Bacterin+IMS

4/8

0/8

2/8

4/8

2/8

12/40

0.300

Bacterin+VapA+IMS

0/8

0/8

0/8

2/8

1/8

3/40

0.075

Live

1/8

0/8

3/8

6/8

2/8

12/40

0.300

*Isolation number/**Total organ number.

adjuvant did not affect the antibody or DTH responses,
a Th2 response directly and significantly reduced or
removed the immune efficacy. Although the formation
of a cytokine response to antigens was developed as an
indirect assessment, evaluations of potential immunity
against antigens should be direct in immunocompetent
mice. In the present study, to demonstrate the efficacy of
the VapA virulence factor during vaccination, this protein
was added to bacterin vaccines (18).
Murine models of R. equi infection demonstrated
that a cell-mediated immune response is essential for
the clearance of the organism (19). Vanniasinkam et
al. (20) reported that Th1 responses increased after the
coadministration of a DNA vaccine and IL-2 plasmid
expression in a model in BALB/c mice; however, protection
was not observed in vaccinated mice when the mice were
challenged with 1 × 107 bacteria/mL of virulent R. equi,
except in mice vaccinated with a live vaccine. In addition,
those authors stated that vaccines developed based on

VapA and recombinant protein in BALB/c mice failed to
prevent bacterial replication after challenge at high doses.
Both humoral and cellular immunity have been
reported to be necessary for the disposal of R. equi. In
experimental trials with hyperimmune plasma, CD4+
and CD8+ T cells may reduce the number of bacteria in
the lungs. While clearance was accomplished via type 1
immune responses, type 2 responses may fail to clear the
bacteria, leading to the development of lesions (21). The
relationship between protection and a high anti-VapAIgG antibody titer was emphasized in vaccinated mice
(22,23). Haghighi and Prescott (24) reported high IgG2
antibody titers in mice vaccinated with a VapA-DNA
vaccine compared to control mice and compared to mice
vaccinated with a VapA-pcDNA vaccine and an IL-12plasmid vaccine.
In this study, the highest antibody titer was observed
in mice vaccinated with the bacterin+VapA+IMS and
bacterin+IMS vaccines. In addition, antibody titers
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began to rise and stabilize earlier in mice immunized
with a bacterin+VapA+IMS vaccine than in control mice.
However, a significant reduction in the antibody titers
of vaccinated mice was observed after challenge. The
explanation for this situation was considered to be the
neutralization of challenge antigen with antibody.
Lopez et al. (25) reported that an attenuated riboflavin
autotrophic R. equi strain was capable of INF-g expression
in immune-suppressed BALB/c mice. In addition,
protection against challenge with R. equi was observed
in mice. IFN-g positivity was significantly higher in the
vaccine group than in the control group in the challenge
and seropotency tests of our study. The maximum
numbers of IFN-g-positive samples were observed in the
bacterin+VapA+IMS (0.750) and bacterin+IMS (0.687)
vaccine groups. Oliveira et al. (23) vaccinated mice twice
with Salmonella Typhimurium containing cloned VapA
antigen and challenged the mice intravenously with R. equi
2 weeks after the last vaccination. Those authors reported
high IL-12 levels in tissue homogenates of vaccinated
mice, as indicated by ELISA; however, low TNF and IL-4
levels were observed.
In the challenge and seropotency tests of our study, IL4-positive samples were detected only in mice vaccinated
with live vaccines. IL-4 positivity could not be determined
in control mice or in the other vaccine groups. Thus,
we concluded that the determination of IL-4 was not an
appropriate criterion for studies assessing vaccine efficacy.
Prescott et al. (18) reported that the bacterial
clearance rate increased in the internal organs of CD1
mice vaccinated with the nonadjuvant VapA vaccine.
However, no changes were reported in BALB/c mice. In
addition, the use of adjuvants (i.e. Al(OH)3 and immunestimulating complexes (ISCOMs)) significantly increases
the immunogenicity of the VapA antigen; ISCOMs
were nonimmunogenic, and Th2 immunity was better
stimulated by the Al(OH)3 adjuvant. Phumona et al. (16)
reported that DNA vaccines have specific advantages
compared to classical vaccines. The combined effect of
DNA vaccine candidates (i.e. pcDNA 3-Re-1 and pcDNA3-Re-3 vs. pcDNA) with the R. equi heat shock protein
GroEL2 was demonstrated to protect C3H/He mice
against R. equi infection. Additionally, 7 days after aerosol
challenge, a significant reduction of R. equi numbers in the
lungs was observed in immunized mice. The absence of
significant pathological changes, which reflects complete
protection against R. equi infection, in mouse models may
not accurately reflect the effectiveness of potential vaccine
candidates. Thus, mouse models may not be appropriate
in such vaccine studies. Conversely, Gonzalez-Iglesias et
al. (26) reported that the murine lung infection model
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provides a useful tool for both R. equi virulence and
vaccine studies. Oliveira et al. (23) cloned the R. equi
VapA gene into S. Typhimurium because Salmonella
spp. colonize and persist in mouse lymphoid tissues. In
addition, 2 days after challenge, a 3- to 7-fold increase in R.
equi clearance was observed. A reduction of the number of
bacteria continued during infection in orally immunized
mice. Additionally, bacterial growth was 50-fold lower
in this group than in controls. Severe inflammation and
necrosis occurred in nonimmunized mice, but these
symptoms were 2-fold lower and leukocyte infiltration
was temporary in vaccinated mice. No deaths were
reported in vaccinated mice, and all unvaccinated mice
died. In addition, high anti-VapA IgG antibody levels were
reported to be associated with protection in immunized
mice. We demonstrated that the bacterin+Al(OH)3
vaccine, the bacterin+VapA+Al(OH)3 vaccine, the
bacterin+IMS vaccine, the bacterin+VapA+IMS vaccine,
and the live vaccine provided 9.03-fold, 9.25-fold, 15.23fold, 38.85-fold, and 8.09-fold more bacterial clearance
from the lungs, respectively, compared to control mice.
The immune responses that occur in vaccinated mice
reduce bacterial growth in the lungs.
Haghighi and Prescott (24) immunized C57BL/6
and BALB/c mice with a DNA vaccine constructed by
incorporating VapA into pcDNA3.1. Those authors stated
that the immunization of mice resulted in enhanced
clearance of R. equi from the livers of intravenously
challenged mice compared to controls. In conclusion,
DNA immunization with VapA enhances mouse immune
responses against R. equi infection.
In this study, the reisolation rates of R. equi from the
internal organs were significantly lower in vaccinated
mice than in control mice after challenge. In addition,
the smallest number of R. equi was isolated from mice
vaccinated with the bacterin+VapA+IMS vaccine.
Whitehead et al. (19) reported that mice inoculated with
R. equi 103-103-/pAWVapA and 103-/pNBV1 completely
cleared infection, whereas strain 103-/pAW48A persisted
in 47% of mice.
Consequently, the bacterin+VapA+IMS vaccine is the
most effective vaccine against R. equi infection in a mouse
model. The vaccination of pregnant mares with this vaccine
for hyperimmune colostrum and plasma production may
be useful for protecting foals against R. equi infection.
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